CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, today announced the appointment of Stephen K. Carter, M.D. to its Board of Directors. Dr. Carter brings extensive scientific, medical and clinical development expertise in oncology to Curis, having held executive-level clinical development positions with Bristol Myers-Squibb Pharmaceuticals and Boehringer Ingelheim Pharmaceuticals.
